HC Wainwright & Co. Reiterates Buy Rating on Insmed Incorporated (INSM)

Market Context

Insmed Incorporated operates in the Healthcare sector. The stock currently trades at $98.56 with a market capitalization of $41.6B. The stock has declined 40.0% over the past 52 weeks.

Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Insmed Incorporated.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for Insmed Incorporated

Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Oct 12, 2026	Wolfe Research	Peer Perform	N/A
Oct 12, 2026	HC Wainwright & Co.	Buy	N/A
Sep 30, 2026	Barclays	Overweight	N/A
Sep 24, 2026	Goldman Sachs	Buy	N/A
Sep 15, 2026	Roth Capital	Buy	N/A

Related Tools: Analyst Ratings Dashboard | View INSM Stock Page